中华医学杂志（英文版）2023，Vol.136Issue(18)：2156-2165,10.DOI:10.1097/CM9.0000000000002750
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection:A systematic review and network meta-analysis
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection:A systematic review and network meta-analysis
Yan Li 1Xueyan Liang 2Huijuan Li 2Xiaoyu Chen3
作者信息
- 1. Department of Pharmacy,Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi 530021,China
- 2. Phase 1 Clinical Trial Laboratory,Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi 530021,China
- 3. Department of Pharmacy,Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi 530021,China||Phase 1 Clinical Trial Laboratory,Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi 530021,China
- 折叠
摘要
关键词
Non-small cell lung cancer/Immune checkpoint inhibitor/Programmed death ligand 1/Cemiplimab/Bayesian net-work meta-analysisKey words
Non-small cell lung cancer/Immune checkpoint inhibitor/Programmed death ligand 1/Cemiplimab/Bayesian net-work meta-analysis引用本文复制引用
Yan Li,Xueyan Liang,Huijuan Li,Xiaoyu Chen..Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection:A systematic review and network meta-analysis[J].中华医学杂志（英文版）,2023,136(18):2156-2165,10.
